Search

A 74-year-old woman with central nervous system-relapsed mantle cell lymphoma experienced grade 1 cytokine release syndrome and grade 2 immune effector cell-associated neurotoxicity syndrome during treatment with brexucabtagene-autoleucel. She also showed a lack of efficacy with various other treatments, including rituximab, ibrutinib, methotrexate, cytarabine, dexamethasone, and tocilizumab. Despite these challenges, the woman achieved complete remission of mantle cell lymphoma after treatment with brexucabtagene-autoleucel. [Extracted from the article]

A 74-year-old man with diffuse large B-cell lymphoma developed cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) during treatment with axicabtagene ciloleucel. Despite receiving tocilizumab, dexamethasone, anakinra, and methylprednisolone for ICANS, the patient did not show any improvement (lack of efficacy). His condition worsened, and he eventually died after three months of symptom onset. Autopsy was not performed. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 21-year-old woman developed cytokine release syndrome and macrophage activated syndrome during treatment with AUTO-3 for Philadelphia chromosome-like B-lymphoblastic leukaemia (Ph-like ALL). Additionally, she also developed macrophage-activated syndrome, which was characterised by high fever, an increase of ferritin, fibrinogen depletion and decreased natural killer (NK) cell activity. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 66-year-old woman developed immune effector cell associated neurological syndrome during treatment with axicabtagene ciloleucel for refractory diffuse large B cell lymphoma. However, she was admitted to intensive treatment unit with grade 4 immune effector cell associated neurological syndrome and complex partial seizure activity. [Extracted from the article]